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The present study investigated associations of two functional MMP12 polymorphisms with
PD risk and cognitive impairment in PD. A total of 478 study subjects (241 PD and 237 age and
sex matched controls) were included in the study. UPDRS score, Hoehn–Yahr staging and
Schwab–England scale were used to assess motor abilities and activity during daily life. All
patients were classiﬁed into groups with dementia (PDD, n = 72) and without dementia (nPDD,
n = 159) based on the neuropsychological assessment. The two most common functional single
nucleotide polymorphisms (SNPs) in MMP12 gene were determined using TaqMan real-time
PCR assays. Frequencies of evaluated MMP12 rs2276109 alleles and genotypes were similar in PD
and the controls, whereas rs652438G allele genotypes were signiﬁcantly more frequent among
healthy individuals ( p = 0.013, OR 0.47 (0.26–0.85). The rs2276109 and rs652438 allele and
genotype frequencies were not associated with dementia in PD patients.
The current results suggest that MMP12 rs652438 but not MMP12 rs2276109 may affect the
risk for PD, as the minor G allele genotypes might be a protective factor.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Neurodegenerative diseases like Parkinson's and Alzheimer's
constitute one of the major health problems in the elderly
population. The mechanism of neurodegeneration has not* Corresponding author.
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inﬂammation in the pathogenesis of PD gained ground [1]. The
neuroinﬂammation, deﬁned as inﬂammation of the nervous
tissue, can protect the CNS against harmful stimuli, but the
primary initiation of a cascade of events, such as production ofpum.edu.pl (M. Kurzawski), tvlaykov@mf.uni-sz.bg (T. Vlaykova),
nna.pierzchlinska@pum.edu.pl (A. Pierzchlińska), drozdzik@pum.
p. z o.o. All rights reserved.
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chronic inﬂammatory state. Microglia, the resident immune
cells of the central nervous system, play an important role in
maintaining homeostasis. Under physiological conditions,
number and function of microglia are controlled by the local
microenvironment. However, the process of neurodegenera-
tion can promote microglial activation, also known as
'microglial priming', and switches them from a protective to
an aggressive phenotype with enhanced synthesis of pro-
inﬂammatory mediators, such as reactive oxygen species
(ROS), nitric oxide (NO) and metalloproteinases (MMPs). It is
interesting that a common feature of neurodegenerative
disorders is the presence of activated microglia in areas of
neuronal death [2]. Astrocytes appear to play a similar role to
microglia in inﬂammatory responses of the CNS. They also
produce different inﬂammatory mediators, for example, IL-2
and IL-1, thereby stimulating CD4+ T helper cells to produce
granulocyte-macrophage colony stimulating factor (GM-CSF),
which contribute to recruitment of CD11b-positive myeloid
cells and propagation of inﬂammation processes [3]. CD4+ and
CD8+ T cells can secrete cytokines and MMPs that are not only
toxic to neurons but also can lead to vascular leakage and
consequently the blood-brain barrier (BBB) damage. The
disrupted BBB permits the entry of immune cells from
periphery, thus converting acute inﬂammation into a chronic
inﬂammatory state.
The loss of dopaminergic neurons in PD is usually
associated with glial reaction, particularly the activation of
immunocompetent microglia cells. The post mortem exami-
nation of substantia nigra of PD patients has shown CD+ T cell
inﬁltration, accompanied by morphologically and functionally
changed microglia cells and astrocytes. There is evidence that
direct injection of a-synuclein into the substantia nigra leads
to upregulation of mRNA expression of proinﬂammatory
cytokines producing several factors, including MMPs [4].
Matrix metalloproteinases (MMPs) are a growing family of
zinc-bound endopeptidases, divided into ﬁve subgroups that
include collagenases, gelatinases, stromelysins, membrane-
type (MT)-MMPs and others. Most MMPs are expressed at low
levels under normal physiological conditions (MMP2, MMP9),
and serve rather as neuroprotective factors. However, upre-
gulation of certain MMPs has been reported in Parkinson's
disease (PD) [5]. A number of studies have demonstrated that
neuronal death in PD can be connected with two pathways, i.e.
apoptosis and necrosis. Apoptotic cells trigger recruitment of
phagocytic cells releasing chemoattractants. Cho et al., and
Sugama et al., showed that microglia were rapidly activated by
apoptotic dopamine neurons in the substantia nigra after axon
transection, and that phagocytosis of apoptotic neurons by
activated microglia occurred at early stages of apoptosis [6,7].
Macrophage metalloelastase (MMP12) was ﬁrst identiﬁed as
an elastolytic metalloproteinase secreted by inﬂammatory
macrophages. The expression of MMP12 has been revealed in
hypertrophic osteoclasts, vascular smooth muscle cells, and
the CNS [8,9]. Crocker et al., and other authors showed
constitutively high level of MMP12 in microglia in the CNS, and
proved its contribution to neuroinﬂammation [10–13]. Simi-
larly to other MMPs, MMP12 could play a dual role in the
pathogenesis of inﬂammatory diseases. MMP12 was demon-
strated to be involved in progression of spinal cord trauma,intracerebral hemorrhage by disrupting BBB functions or
triggering macrophage recruitment into the CNS. On the other
hand, MMP12 inhibited pathogenesis of experimental autoim-
mune encephalomyelitis by enhancing anti-inﬂammatory
effects [14].
Genetic variations of pro- and anti-inﬂammatory cyto-
kines' genes, located within promoter regions, are considered
to be involved in PD. Bialecka et al., revealed that TNF308AA
genotype might increase the risk of early onset of PD [15].
However, associations between genetic polymorphisms of
MMP in relation to the risk of PD have not been extensively
studied. Chen et al. examined the impact of the genetic
polymorphisms of MMP3, MMP2, MMP9 and tissue inhibitors of
metalloproteases (TIMPs) TIMP-2 and TIMP-1 coding genes
with PD. They demonstrated modest association of MMP9
rs17576 AA genotype with PD susceptibility and a protective
effect of TIMP1 rs4898C allele in PD [1]. Another study assessed
the correlation between cerebral MMP12 expression in the
aged brain. Result of the study conducted by Liu et al.,
suggested that upregulated cerebral MMP12 during aging
enhanced aging associated with neuroinﬂammmation by
facilitating recruitment of bone marrow-derived microglia
into the brain [9]. Over the last few decades, several factors
have been identiﬁed as main players of neurodegeneration in
the nigrostriatal system. Cytokines such as IL-2, IL-4, IL-6, IL-
10, TNF-a, and IFN-g are increased in serum of PD patients.
Consistent with the aforementioned events, genetically
inherited changes in MMPs expression might contribute to
upregulation of cytokines and inﬂuence susceptibility to PD.
The present study aims to evaluate the most common
functional MMP12 gene polymorphisms associations with
PD in a Polish population.
2. Materials and methods
2.1. Subjects
Consecutive 241 PD patients of Caucasian origin (127 males
and 114 females), aged from 25 to 89 years (64.17  10.13 years),
PD diagnosed, and conﬁrmed during follow-up visits, accord-
ing to the UK Parkinson's Disease Society Brain Bank Clinical
Diagnostic Criteria were recruited in Outpatient Movement
Disorder Clinics at two Polish centers (Gdansk, Szczecin) [16].
Clinical stage of the disease was rated according to Hoehn and
Yahr and severity of motor symptoms was assessed with the
Uniﬁed Parkinson's Disease Rating Scale (UPDRS) (parts II–IV)
[17]. All patients with clinical symptoms suggesting secondary
causes of parkinsonian syndrome (vascular, drug-induced),
with features suggestive of atypical parkinsonian syndromes
(multiple system atrophy, progressive supranuclear palsy and
corticobasal syndrome) were excluded from ﬁnal data analysis.
Control samples were obtained from 237 randomly selected
healthy individuals (112 males and 125 females), aged 25–88
years (64.86  9.43 years) from the same geographical region as
the patients, matched by sex, age and ethnicity (all of Caucasian
origin) to avoid the inﬂuence of population stratiﬁcation.
All participants were assessed with Mini-Mental State
Examination (MMSE) and Beck Depression Inventory (BDI) to
screen for dementia and depression [18,19]. The control
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demented (≥25 in MMSE), did not demonstrate any parkinso-
nian symptoms on neurological examination, had no history
of stroke and did not suffer from any liver and kidney
dysfunction. All patients who met inclusion criteria under-
went detailed neuropsychological examination described
previously [20]. According to the results of investigations,
patients were classiﬁed as non-demented (nPDD) and dement-
ed (PDD) according to Emre et al. criteria [21]. The demographic
and clinical characteristics of the Parkinson's disease patients
with or without dementia are shown in Table 1.
The protocol of the study was approved by the relevant
local ethics committees, and study participants provided
written informed consent.
2.2. Genetic study
Genomic DNA was extracted from buccal swab samples from
241 PD patients and 237 control subjects, using Quick Blood
DNA Puriﬁcation Kit (EurX, Poland), and subsequently stan-
dardized to equal concentrations of 10 ng/ml, based on
spectrophotometric absorbance measurement (260/280 nm).
Genotyping for a presence of MMP12 rs2276109:A>G (located in
gene promoter, 82A>G) and rs652438:A>G (exon 8, Asn357-
Ser) single nucleotide polymorphisms (SNPs) was performed
using pre-validated allelic discrimination TaqMan real-time
PCR assays (assay IDs: C__15880589_10 and C____785907_10,
Life Technologies, USA), and TaqMan GTXpress Master Mix
(Life Technologies, USA). All reactions were run in a ﬁnal
volume of 12 ml. Fluorescence data was captured using ViiA7
Real-Time PCR System (Applied Biosystems, USA) after 40
reaction cycles. Speciﬁc genotypes were assigned to individual
samples after analysis with TaqMan Genotyper Software
(Thermo Fisher Scientiﬁc, USA).
2.3. Statistical analysis
Concordance of genotype distribution with Hardy–Weinberg
equilibrium was assessed using the x2 exact test. Genetic case-
control analyses between study groups were performed usingTable 1 – Demographic and clinical characteristics of non-dem
Demographic and clinical data nPDD (n = 15
Females/Males 84/75 
Mean age and range (years) 62.1  9.6
39–89
Age at disease onset and range (years) 56.0  11.0
28–87
Disease duration (years) 6.1  4.8 
Hoehn–Yahr disease stage 2.02  0.74
(n = 154)
Daily levodopa dosage (mg) 698  439
(n = 152)
MMSE score 28.1  1.9
(n = 158)
ns – not signiﬁcant.
* Fisher test.
** t-Student test.
*** p values were calculated according to the Mann–Whitney U test.the Fisher exact test. Odds ratios (OR) and 95% conﬁdence
intervals (95% CI) were calculated using the Newcombe–
Wilson method without the continuity correction. Data
alignment with normal distribution was tested by means of
Shapiro–Wilk test, and further analyses were performed by
means of t-Student test or Mann–Whitney U-test. The General
Linear Model (GLM) was used for multivariate analysis. A p
level of less than 0.05 was considered statistically signiﬁcant.
Calculations were performed using the Statistica 9.1 software
package (StatSoft, Krakow, Poland).
3. Results
3.1. Demographic and clinical characteristics of PD
patients
In the group of 241 PD patients enrolled to the study, 72
individuals fulﬁlled the criteria for dementia. nPDD and PDD
did not differ in sex, mean age, age at disease onset, whereas
the disease duration was signiﬁcantly shorter in nPDD group
(6.1  4.8 vs. 8.3  5.9, p = 0.036). The daily levodopa dosage
was signiﬁcantly lower in non-demented group (698  439 mg)
in comparison to PD with dementia (792  427 mg, p = 0.046).
Both Hoehn–Yahr disease stage and MMSE score were
associated with dementia status (H–Y disease stage in nPDD
group: 2.02  0.74, in PDD group: 2.54  0.95, p < 0.0001; MMSE
score: 28.1  1.9 in nPDD group and 23.6  4.2 in PDD group,
p < 0.0001).
3.2. MMP12 polymorphism in PD patients and controls
The observed distribution of MMP12 genotypes was in
concordance with the Hardy–Weinberg equilibrium, both in
PD and control groups ( p > 0.1). Frequency of MMP12
rs2276109:A>G genotypes and alleles was similar in PD
patients and healthy individuals (Table 2). In case of
rs652438:A>G missense, minor G allele (357Ser) was found
with signiﬁcantly lower frequency in PD group, compared to
the controls (3.7% vs. 7.6%, p = 0.011), and minor allele carrierented (nPDD) and demented (PDD) patients (mean W SD).
9) PDD (n = 72) p value
37/35 n.s.*
69.3  8.8
35–85
p = 0.441**
60.9  10.4
29–80
p = 0.637**
8.3  5.9 p = 0.036**
2.54  0.95
(n = 68)
p < 0.0001***
792  427
(n = 70)
p = 0.046***
23.6  4.2
(n = 71)
p < 0.0001***
Table 2 – Frequencies of the studied SNPs in PD patients and healthy controls.
PD patients
n = 241
Healthy controls
n = 237
p value OR (95%CI)
n % n %
MMP12 rs2276109:A>G
AA 182 75.5 187 78.9
AG 52 21.6 41 17.3 0.296 1.30 (0.82–2.06)
GG 7 2.9 9 3.8 0.799 0.80 (0.29–2.20)
AG or GG 59 50 0.385 1.21 (0.79–1.86)
Minor (G) allele freq. 13.7 12.4 0.631 –
MMP12 rs652438:A>G
AA 223 92.5 202 85.2
AG 18 7.5 34 14.3 0.018 0.48 (0.26–0.88)
GG 0 0.0 1 0.4 0.476 –
AG or GG 18 7.5 35 14.8 0.013 0.47 (0.26–0.85)
Minor (G) allele freq. 3.7 7.6 0.011 –
p values for alleles and genotypes calculated by means of Fisher exact test in relation to major allele or homozygotes for a major allele.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 3 4 7 – 3 5 3350status (AG or GG genotype) was associated with over two-fold
reduced odds for PD (OR = 0.47, p = 0.013, Table 2).
Performed linkage analysis have shown that the studied
MMP12 SNPs (rs2276109:A>G and rs652438:A>G) are in full
linkage disequilibrium (D' = 1.000, r2 = 0.009), and minor alleles
are never observed simultaneously on the same chromosome
in the studied population, leading to the presence of only 3
(from 4 potentially possible) haplotypes (i.e. A–A, G–A and A–
G). The A–G haplotype has been found with signiﬁcantly lower
frequency among PD patients (Table 3) and the A–A/A–G
diplotype determined 2-fold lower risk for PD than the most
common A–A/A–A diplotype (OR = 0.5, p = 0.031, Table 3).
3.3. MMP12 polymorphism in nPDD and PDD patients
When MMP12 genotypes were analyzed in PD patients divided
into two groups, based on the aforementioned diagnostic
criteria for dementia, no signiﬁcant differences in the
genotypes distribution nor in allele frequencies were observed
(Table 4).Table 3 – MMP12 Haplotypes and diplotypes in PD patients an
PD patients
n = 241
Health
n
n % n 
MMP12 diplotype
A-A/A-A 165 68.5 154 
A-A/G-A 51 21.2 39 
A-A/A-G 17 7.1 32 
G-A/G-A 7 2.9 9 
G-A/A-G 1 0.4 2 
A-G/A-G 0 0.0 1 
MMP12 haplotype
A-A 398 82.6 379 
G-A 66 13.7 59 
A-G 18 3.7 36 
Haplotypes reconstructed from rs652438:A>G and rs2276109:A>G genoty
Fisher exact test in relation to major haplotype or homozygotes for a m
haplotypes.4. Discussion
The inﬂuence of genetic factors on Parkinson's disease has
been proposed and the search for their deﬁnition is ongoing
[22]. Currently, PD ethiopathogenesis is described as the
interaction of variety of factors, including aging, environmen-
tal, immunological and genetic factors. Recently, the review of
current publications, has once again drawn the attention to
neuroinﬂammation and its connections with autoimmune
mechanisms underlying the process of a-synuclein accumu-
lation in the midbrain of PD patients. A signiﬁcant level of
cytokines such as IL-2, IL-4, IL-6, IL-10, TNF-a, and IFN-g in the
SN (substantia nigra) and CSF of PD patients has been reported,
however, it has not been clearly established whether neuroin-
ﬂammation protects or promotes the neurodegeneration [23].
Matrix metalloproteinases, including MMP12, may be one of
the important players in the cascade of SN degeneration. The
level of MMPs is increased in the presence of an external
trigger, and activated MMPs can inﬂuence many factors, suchd control group.
y controls
 = 237
p value OR (95%CI)
%
65.0 0.438a 1.17 (0.80–1.70)
16.5 0.473 1.22 (0.76–1.95)
13.5 0.031 0.50 (0.26–0.93)
3.8 0.613 0.72 (0.26–2.00)
0.8 0.612 0.47 (0.04–5.20)
0.4 0.484 –
80.0 0.320a –
12.4 0.773 –
7.6 0.011 –
pes; p values for haplotypes and diplotypes calculated by means of
ajor haplotype, except acalculated in relation to all other diplotypes/
Table 4 – Frequencies of the studied SNPs in PD patients with (PDD) and without dementia (nPDD).
PDD patients
n = 72
nPDD patients
n = 159
p value OR (95%CI)
n % n %
MMP12 rs2276109:A>G
AA 56 77.8 119 74.8 0.741a 1.18 (0.61–2.28)
AG 14 19.4 35 22.0 0.728 0.85 (0.42–1.70)
GG 2 2.8 5 3.1 1.000 0.85 (0.16–4.51)
Minor (G) allele freq. 12.5 14.1 0.664 –
MMP12 rs652438:A>G
AA 69 95.8 145 91.2 0.281a 2.22 (0.61–7.98)
AG 3 4.2 14 8.8 0.281 0.45 (0.11–1.62)
GG 0 0.0 0 0.0 – –
Minor (G) allele freq. 2.1 4.4 0.291 –
p values for alleles and genotypes calculated by means of Fisher exact test in relation to major allele or homozygotes for a major allele, except
acalculated in relation to minor allele carriers.
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For example, MMP12 was suggested to function as TNF-a
converting enzyme leading to liberation of active form of that
pro-inﬂammatory cytokine by shedding it from the cell
membrane, where the pro-form is typically bound [24]. In
our study we hypothesized that different functional variants
in MMP12 gene, which are shown to affect the expression and
activity of the enzyme, may be important in mediating
susceptibility to PD and cognitive impairment development.
In the performed analysis, the frequencies of minor MMP12
rs652438:G allele and G allele genotypes were signiﬁcantly
higher in the healthy subjects compared with the PD patients
( p = 0.011 and p = 0.013, OR 0.47 (0.26–0.85)). It may suggest a
protective role of the G allele, which seems to decrease more
than 3-fold the activity of MMP12 due to missense change of
asparagine to serine in haemopexin domain and alteration of
substrate binding [25]. Our results are in line with the ﬁndings
of Haq et al., who reported that the examined alteration in the
aforementioned SNP was associated with severity of emphy-
sema in lungs of patients with chronic obstructive pulmonary
disease (COPD), with A/A homozygotes having more severe
emphysema, in contrast to G allele carriers whose MMP12
exhibit lower activity [25]. In fact, MMP12 (/) knock-out mice
were completely protected from development of emphysema
and had impaired recruitment of monocytes/macrophages
into the lung [26,27]. Moreover, Egeberg et al. investigated the
risk of incident (new-onset) Parkinson disease in patients with
rosacea. They showed not only a 2-fold increased risk of PD in
patients diagnosed with ocular rosacea (adjusted IRR, 2.03 [95%
CI, 1.67–2.48]), but also revealed that tetracycline therapy
appeared to reduce the PD risk (adjusted IRR, 0.98 [95% CI, 0.97–
0.99]) [28]. One of the possible explanations of those ﬁndings
could be related to elevated matrix metalloproteinase activity.
MMP12 seems to be a marker of inﬂammatory activation. The
increased level of MMP12 was observed in chronic obstructive
pulmonary disease, atherosclerosis and multiple sclerosis
[27–30]. Chehaibi et al., investigated the association between
MMP1-16071G/2G, MMP12-82A/G (rs2276109) and MMP12
1082A/G (N357S, rs652438G) (being also investigated in the
present study) genotypes and haplotypes and the risk of
ischemic stroke (IS) in patients with type 2 diabetes mellitus(T2DM). The 82G/1082G (rs652438:G, rs2276109:G) haplotype
of MMP12 was associated with higher risk of diabetes
( p = 0.029) and of ischemic stroke in diabetic patients
( p = 0.032), and thus MMP12 polymorphism can be considered
a potential marker of cerebrovascular disorders in diabetic
patients [31]. In our study the A–G haplotype has been found
with signiﬁcantly lower frequency among PD patients, and
may be considered as a protective factor for PD development
than the A–A haplotype. Upregulation of MMP12 expression
depends on MMP12 gene promoter, which contains an AP-
binding site. TNF-a and IL-1b can induce, whereas TGF-b1
inhibits MMP12 expression. Liu et al. assessed changes in
MMP12 concentration in 3-, 10-, and 18-month-old mice. Both
MMP12 mRNA and protein expression were upregulated in
aged brains. Moreover, they demonstrated that MMP12
deﬁciency reduced the ability of macrophages to cross the
transwell membrane and decreased neuroinﬂammation in
aged but not in young mice [9].
The predictors of PDD in the examined group of PD patients
consisted of disease duration, advanced motor disability as
well as daily levodopa dose. We failed to ﬁnd any correlation
between cognitive impairment and MMP12 rs2276109:A>G
polymorphism. Several similarities have been noticed in the
pathogenesis of Parkinson's and Alzheimer's diseases, includ-
ing abnormal protein aggregation. The relationship between
amyloid-b peptide (Ab) and MMP12 has been suggested. In the
research performed by Ito et al., there was a signiﬁcant
increase in MMP12 mRNA as well as protein expression in the
presence of Ab1–42. However, it is inconclusive whether MMPs
promote pathogenic plaque degradation, or contrarily, impair
brain matrix, leading to progression of the disease [32]. In our
study, we found no statistically signiﬁcant impact of MMP12
polymorphisms on the risk of dementia. Nevertheless,
quantitative analyses, e.g. real time quantitative PCR, might
have altered the results.
5. Conclusions
We provide one of the ﬁrst reports evaluating the association
of MMP12 gene polymorphisms and PD. Our study suggests
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 1 ( 2 0 1 7 ) 3 4 7 – 3 5 3352that the rs652438:A>G SNP may inﬂuence the risk for sporadic
Parkinson's disease, but not for dementia in the course of the
disease. The minor G allele of the rs652438:A>G SNP can be
considered as a protective factor against PD, probably because
of decreased activity of MMP12. Future studies to evaluate
interactions of other metalloproteinase genes' polymorphisms
with Parkinson's disease would provide further valuable
information about underlying pathophysiology of the disease.
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